Regeneration Biomedical

05/29/2026

New findings from RBI's completed Phase 1 Alzheimer's study demonstrated improvements in cognitive measures and cerebrospinal fluid (CSF) proteomic biomarkers following treatment with direct-to-brain autologous stem cells.

Read the full press release here:
https://apnews.com/press-release/ein-presswire-newsmatics/rbis-phase-1-first-in-mankind-direct-to-brain-stem-cells-show-improved-csf-proteomics-cognition-in-alzheimers-2c79968fa04ea27960c401e2d8819725

Presented at ISCT 2026 in Dublin May 6-9: intracerebroventricular injections showed sustained CSF, amyloid PET, cognitive improvements in Alzheimer’s disease.

04/24/2026

Regeneration Biomedical will be delivering a podium presentation at the 2026 ISCT Annual Meeting, presenting to an international audience of scientists and physicians on advancements in regenerative neurotherapeutics.

01/06/2026

Regeneration Biomedical has strengthened its intellectual property portfolio with a newly allowed U.S. patent covering its direct-to-brain, Wnt-activated autologous stem cell technology for Alzheimer’s disease. This milestone supports continued innovation and clinical development in regenerative neurotherapeutics.



https://www.einpresswire.com/article/876393541/regeneration-biomedical-strengthens-ip-portfolio-with-direct-to-brain-wnt-activated-stem-cell-patent-for-alzheimer-s

12/02/2025

Regeneration Biomedical will present Phase 1 clinical results of its direct-to-brain autologous stem cell therapy for Alzheimer’s disease at CTAD 2025. With Phase 1 complete, the FDA has cleared RBI to advance into a 110-patient Phase 2 Alzheimer’s trial.

12/01/2025

Regeneration Biomedical has received clearance to initiate its Phase 2A Alzheimer’s clinical trial. This next stage of research will evaluate repeated intraventricular dosing of autologous, Wnt-activated stem cells in patients with mild to moderate Alzheimer’s disease.

An expanded funding commitment of up to $25 million from PFD Capital Partners will support trial launch, site activation, and the broader clinical program.

12/01/2025

Regeneration Biomedical is honored to receive the 2025 Judges’ Choice Award at the Octane Medical Innovation Forum. This recognition highlights our innovation, scalability, leadership, and the potential impact of our autologous stem cell platform on neurodegenerative disease care.

Thank you to the Octane judges and everyone supporting this work.

09/25/2025

Watch Dr. Christopher Duma LIVE as he shares groundbreaking insights on treating neurodegenerative disorders using autologous fat-derived stem cells. Learn about promising Phase 1 results and the upcoming FDA-approved Phase 2 trial for Alzheimer's patients. This is regenerative medicine in action!

Watch here: https://tinyurl.com/2twdrtr9

08/27/2025

Associated Press Exclusive: Safe, Direct-to-Brain Autologous Stem Cell Therapy Shows Promise in Alzheimer’s

Read Here:

A Phase 1, "first-in-mankind" trial of stem cells injected directly into the brain, is safe with early signs of efficacy; FDA submission made for Phase 2 trial.

08/27/2025

Drug Target Review has published a full-length feature on Dr. Christopher Duma and Regeneration Biomedical’s novel stem cell approach to treating Alzheimer’s disease.
The article explores how Wnt-activated autologous stem cells and direct delivery into the brain’s ventricles could open a new frontier in tackling neurodegeneration.
Read the full feature here:
https://www.drugtargetreview.com/article/184013/inside-the-alzheimers-study-backing-stem-cells-not-drugs/

Discover the challenges in Alzheimer therapy and how Dr Christopher Duma is pioneering a new treatment direction.

07/31/2025

We’ve been featured in Precision Medicine Group alongside other biotech innovators developing next-generation gene and autologous cell therapies for Alzheimer’s disease.

The article highlights the growing momentum behind disruptive approaches aimed at addressing the urgent, unmet need for more effective treatments. Our founder, Dr. Christopher Duma, shares insights on our novel delivery method, stem cell approach and encouraging Phase 1 clinical trial data.

Read the full article here to learn more: https://www.precisionmedicineonline.com/neurological-psychological-disorders/reverse-alzheimers-disease-biotechs-betting-next-gen-cell-gene

The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life benefits to be cost-effective.